AstraZeneca

Open: 63.24 Close: 63.17 Change: -0.07

How to know if AstraZeneca is a risky investment without reading the whole internet.

This document will help you to evaluate AstraZeneca without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, report, revenue, share, agreement, Eccogene, profit, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

UK drugmaker signs agreement with Chinas Eccogene to work on an obesity and type 2 diabetes pill. ECC5004 touted as having fewer side effects than other oral GLP-1s with efficacy on par with competitors in this class.

Today's News

UK drugmaker signs agreement with Chinas Eccogene to work on an obesity and type 2 diabetes pill. AstraZeneca reported a 5% rise in revenues to $33.8bn in the first nine months of the year. ECC5004 touted as having fewer side effects than other oral GLP-1s with efficacy on par with competitors in this class Novo Nordisk has said it plans to submit its obesity pill to U.S. market. AstraZeneca reported core profit per share of $1.73 for the third quarter. China accounted for 13% of Astra Zenecas revenue last year. China accounts for 13 percent of the companys revenue. AstraZeneca announced results from the Phase III Emerald-1 trial “demonstrated a statistically significant clinically meaningful improvement” in the primary endpoint of progression-free survival. Astrazenecas imfinzi, chemo combo meets endpoint in phase III liver cancer. AstraZeneca raises full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines. Eccogene enters exclusive license agreement with astrazeneca to develop and commercialize small molecule GLP-1 receptor agonist ecc5004 for cardiometabolic diseases. Astrazeneca PLC (AZN) on Thursday reported third-quarter profit of $1.37 billion. AstraZeneca shares have declined slightly more than 6%. AstraZeneca PLC ADR underperforms Friday when compared to competitors - MarketWatch. Eccogene enters exclusive license agreement with astrazeneca to develop and commercialize small molecule glp-1 receptor agonist ecc5004 for cardiometabolic diseases. Eccogenes ECC5004 small molecule GLP-1RA for any indication in all territories except China. AstraZeneca posts 16% drop in Q3 2023 profit after tax. Earnings per share (EPS) on a reported basis dropped by 16% to $0.89 from $1.06 in QQ3 2022. Company plans to work together to increase RNG yield.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, report, revenue, share, agreement, Eccogene, profit, and the most common words in the summary are: astrazeneca, news, best, business, company, bloomberg, drug, . One of the sentences in the summary was: ECC5004 touted as having fewer side effects than other oral GLP-1s with efficacy on par with competitors in this class.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #news #best #business #company #bloomberg #drug.